Develops treatments for central nervous system disorders and rare diseases, focusing on innovative therapies.
Seelos Therapeutics, Inc. is a dynamic clinical-stage biopharmaceutical company based in New York, New York, dedicated to advancing therapies for a spectrum of disorders affecting the central nervous system, respiratory system, and beyond. At the forefront of its portfolio are several pioneering programs. Among them, SLS-002 stands out as an intranasal racemic ketamine treatment aimed at alleviating acute suicidal ideation and behavior in individuals with major depressive disorders. Additionally, SLS-005, a protein stabilizer, targets amyotrophic lateral sclerosis (ALS) and Sanfilippo syndrome, while SLS-006, a partial dopamine agonist, is geared towards enhancing the management of Parkinson's disease (PD).
The company's innovative pipeline extends to preclinical stages with programs like SLS-007, an anti-alpha-synuclein peptidic inhibitor for PD, and SLS-008, an orally available antagonist addressing chronic inflammation in conditions such as asthma and pediatric orphan indications. Further expanding its therapeutic footprint, Seelos Therapeutics is developing SLS-010, an oral histamine H3A receptor antagonist tailored for narcolepsy and related disorders, along with SLS-012, an injectable therapy designed to manage post-operative pain.
Founded in 1987, Seelos Therapeutics, Inc. has evolved into a powerhouse of innovation within the biopharmaceutical sector. Headquartered strategically in New York City, the company continues to push the boundaries of medical research and development, driven by a steadfast commitment to improving patient outcomes across diverse therapeutic areas. With a rich history and a forward-thinking approach, Seelos Therapeutics remains poised to make significant strides in addressing unmet medical needs through its cutting-edge treatments.